Logo

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Share this

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Shots:

  • The company initiates P-II KET-LID clinical trial to evaluate the safety- efficacy- and PK of Ketamine (sub-anesthetic- IV) vs PBO in patients with LID associated with PD. The patient enrollment is expected to initiate in Oct’21 with an anticipated PDUFA date on Q4’21
  • The 1EPs & 2EPs are the changes in the total score & objective score (III- IV) of UDysRS- total daily OFF times as assessed by patients completed 24hrs. diaries along with a total score of UPDRS part III (motor) and sum score of Questions 4.1 and 4.2 (dyskinesia) in part IV
  • The company plans to discuss with the US FDA to initiate a P-III clinical study under the 505(b)2 regulatory pathway in H1’22- based on the P-II results

  | Ref: Globe Newswire | Image: Globe Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions